RAPT
RAPT Therapeutics Inc
NASDAQ: RAPT · HEALTHCARE · BIOTECHNOLOGY
$58.02
+0.00% today
Updated 2026-03-04
Market cap
$1.68B
P/E ratio
—
P/S ratio
411.22x
EPS (TTM)
$-11.66
Dividend yield
—
52W range
$6 – $58
Volume
3.2M
RAPT Therapeutics Inc (RAPT) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $935000.00 | $5.04M | $3.81M | $1.53M | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | +439.3% | -24.4% | -60.0% | -100.0% | — |
| Cost of revenue | $1.38M | $1.24M | $1.33M | — | $996000.00 | $2.81M | $3.55M | $3.54M |
| Gross profit | $-1.38M | $-1.24M | $-1.33M | $5.04M | $3.81M | $1.53M | $-3.55M | $-3.54M |
| Gross margin | — | — | -142.2% | 100.0% | 100.0% | 100.0% | — | — |
| R&D | $25.62M | $31.77M | $34.91M | $45.48M | $56.98M | $67.08M | $101.00M | $107.22M |
| SG&A | $3.71M | $5.18M | $8.72M | $12.77M | $16.04M | $20.24M | $26.06M | $28.88M |
| Operating income | $-29.33M | $-36.95M | $-43.63M | $-53.21M | $-69.21M | $-85.80M | $-127.06M | $-136.10M |
| Operating margin | — | — | -4666.2% | -1055.4% | -1815.1% | -5618.5% | — | — |
| EBITDA | $-27.95M | $-35.71M | $-42.30M | $-52.09M | $-68.21M | $-84.75M | $-125.85M | $-134.90M |
| EBITDA margin | — | — | -4524.0% | -1033.1% | -1789.0% | -5550.0% | — | — |
| EBIT | $-29.33M | $-36.95M | $-43.63M | $-53.21M | $-69.21M | $-85.80M | $-127.06M | $-136.10M |
| Interest expense | $0.00 | $0.00 | $2.62M | $2.44M | $996000.00 | $1.05M | — | — |
| Income tax | — | $800000.00 | $660000.00 | $990000.00 | $-996000.00 | $-1.96M | — | — |
| Effective tax rate | 0.0% | -2.3% | -1.6% | -1.9% | 1.4% | 2.3% | 0.0% | 0.0% |
| Net income | $-29.11M | $-36.15M | $-43.00M | $-52.89M | $-68.21M | $-81.88M | $-116.80M | $-129.87M |
| Net income growth (YoY) | — | -24.2% | -19.0% | -23.0% | -29.0% | -20.0% | -42.6% | -11.2% |
| Profit margin | — | — | -4598.6% | -1049.0% | -1788.8% | -5362.2% | — | — |